Elementus helps solve the toughest blockchain data problems so organizations can navigate web3 safely and with confidence. Its intelligence platform is used by financial institutions to build the future of finance and commerce on the bedrock of blockchain, and by key U.S. governmental agencies to solve some of the most high-profile ransomware investigations. Elementus helps organizations investigate on-chain activities, identify risk, discover valuable market intelligence or a combination of all three. By providing a complete view into flows of funds at the most granular level, Elementus delivers actionable insights and transparency needed to grow and prosper safely in a web3 world.
Region: North America
Eaglebrook Advisors
Eaglebrook is a crypto investment platform that provides RIAs with direct access to bitcoin and digital assets. The firm operates one of the largest SMA Platforms in the crypto market. Eaglebrook’s investment platform offers access to tax optimized Bitcoin and Ethereum separately managed accounts (SMAs) and third-party investment manager strategies held at an institutional qualified custodian.
Dust Identity
DUST Identity is a leading authentication and anchored digital thread solution for real-world objects that connects data to physical things. DUST Identity’s award-winning anchored digital thread solution delivers the ability to track and trace an object’s pedigree and provenance throughout its lifecycle – providing access to the right information at the right place and time.
Coin Metrics
Coin Metrics is the leading provider of crypto financial intelligence, offering network data, market data, indexes and network risk solutions to the most prestigious institutions touching cryptoassets. Coin Metrics was founded in 2017 as an open-source project to determine the economic significance of public blockchains. Today, they expand on that original purpose to empower people and institutions to make informed crypto financial decisions. Coin Metrics aim to usher the world’s premier financial institutions into crypto with the most trusted data and insights.
Casa
Casa is the secure home for your Bitcoin. The Company builds tools at the forefront of Bitcoin self-custody, enabling individuals to take control of their wealth by holding their own Bitcoin private keys in an easy and secure manner. Casa is building for a future where self-custody is default and every individual, family, and business can freely manage their own wealth and data.
Alluvial
Alluvial is a software development company supporting the development of the Liquid Collective protocol. Alluvial is focused on the overall growth and maturity of the ecosystem by fostering participation in proof of stake blockchains. Acquired by Galaxy Digital Inc. in 2025.
Xaira Therapeutics
Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intelligence to learn the language of life and transform how we treat disease. The company seeks to rethink the drug discovery and development process from end-to-end by bringing together leading talent across three core areas: machine learning research to better understand biology, expansive data generation to power new models, and robust therapeutic product development to treat disease.
Metsera
Metsera is a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases. Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and meet the future needs of a rapidly evolving weight loss treatment landscape. Metsera went public in 2025 (NASDAQ: MTSR). The company was subsequently acquired by Pfizer in 2025 and is no longer publicly traded.
nChromaBio
nChroma Bio is a pioneering biotechnology company redefining the future of in vivo targeted genetic medicine to treat a wide array of diseases and bring cures to patients. The company’s integrated product engine tackles significant limitations of existing genetic medicine approaches by enabling safe, precise and specific in vivo delivery. nChroma’s near clinical-stage development candidate, CRMA-1001, is a liver-targeted therapy in development as a potential functional cure for chronic hepatitis B and hepatitis D that leverages the power of epigenetics, nature’s innate mechanism for gene regulation. Guided by a world-class team at the forefront of genetic medicine, founded by renowned pioneers in the field, and supported by top-tier investors, the company is uniquely positioned to deliver groundbreaking therapies with programmable tissue specificity, unlocking highly potent, durable and targeted gene regulation for the liver and beyond.
Engrail Therapeutics
Engrail Therapeutics is a clinical-stage pharmaceutical company with the aspiration of becoming a leader in neuroscience. Their purpose is to deliver transformational therapies that improve the lives of patients with neuropsychiatric and neurodevelopmental diseases.